6-N-丁氧基嘌呤 | 5454-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-N-丁氧基嘌呤
• 英文名称: 6-n-butoxypurine
• 英文别名: 6-butyloxy-9H-purine；6-butoxypurine；F0704-0019；6-butoxy-7(9)H-purine；6-butoxy-1H-purine；6-Butyloxy-purin；6-butoxy-7H-purine
• CAS: 5454-70-6
• 化学式: C₉H₁₂N₄O
• mdl: MFCD00047152
• 分子量: 192.22
• InChiKey: QDZUNLMIDBUULS-UHFFFAOYSA-N

物化性质

• 沸点：
  319.5±52.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2',3'-二脱氧胸苷 、 6-N-丁氧基嘌呤 在 对硝基苯酚 、 potassium phosphate buffer containing 0.004percent potassium azide (buffer A) 、 TPase 作用下， 反应 168.0h， 以36%的产率得到6-butoxy-9-<(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furyl>-9H-purine
  参考文献：
  名称：

  Novel 6-alkoxypurine 2',3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus

  摘要：

  Twenty-one 6-alkoxypurine 2',3'-dideoxynucleosides were enzymatically synthesized with nucleoside phosphorylases purified from E. coli. Eighteen analogs exhibited anti-HIV-1 activity in MT4 cells. Two analogs,6-(hexyloxy)-(17) and 6-(heptyloxy)-(18) purine 2',3'-dideoxynucleoside, were as potent as 2',3'-dideoxyinosine (ddI, didanosine, Videx). Although the antiviral activities of 17 and 18 were equivalent, 18 was more cytotoxic. Analogs containing less than four carbons in the 6-alkoxypurine substituent exhibited weak anti-HIV-1 activity. Analogs containing more than seven carbons in the 6-alkoxypurine substituent were too cytotoxic to be effectively evaluated for antiviral activity. Several 6-alkoxypurine 2',3'-dideoxynucleosides were evaluated for substrate activity with calf intestinal adenosine deaminase (ADA). Increasing the carbon chain length of the 6-alkoxypurine substituent decreased the rate of dealkoxylation. The best substrate in this series was 6-methoxypurine 2',3'-dideoxynucleoside (1); however, the rate of dealkoxylation of 100 muM 1 was 0.17 % of the rate of deamination of 100 muM 2',3'-dideoxyadenosine. Compound 17, the most potent anti-HIV-1 analog, was not a substrate for ADA. EHNA (erythro-9-(2-hydroxy-3-nonyl) adenine), a potent inhibitor of ADA, had little effect on the antiviral activities of 17 and ddI. In contrast, coformycin, a potent inhibitor of both ADA and AMP deaminase, dramatically decreased the antiviral activity of 17, but not the antiviral activity of ddI. Thus, AMP deaminase appeared to be involved in the anabolism of 17. The pharmacokinetic profile of 17, the most promising analog in this series, was determined in the rat. At least seventeen metabolites of 17, including ddI, were detected in plasma samples. This analog also had poor oral bioavailability.

  DOI：

  10.1021/jm00055a009

文献信息

• Gold(I)-Triphenylphosphine Complexes with Hypoxanthine-Derived Ligands: In Vitro Evaluations of Anticancer and Anti-Inflammatory Activities
  作者：Radka Křikavová、Jan Hošek、Ján Vančo、Jakub Hutyra、Zdeněk Dvořák、Zdeněk Trávníček

  DOI：10.1371/journal.pone.0107373

  日期：——

  series of gold(I) complexes involving triphenylphosphine (PPh3) and one N-donor ligand derived from deprotonated mono- or disubstituted hypoxanthine (HLn) of the general composition [Au(Ln)(PPh3)] (1-9) is reported. The complexes were thoroughly characterized, including multinuclear high resolution NMR spectroscopy as well as single crystal X-ray analysis (for complexes 1 and 3). The complexes were screened

  报道了一系列涉及三苯基膦 (PPh3) 和一个 N-供体配体的金 (I) 配合物，该配体来源于一般组成 [Au(Ln)(PPh3)] (1-9) 的去质子化单或二取代次黄嘌呤 (HLn) . 对配合物进行了彻底的表征，包括多核高分辨率 NMR 光谱以及单晶 X 射线分析（配合物 1 和 3）。筛选了复合物对人癌细胞系 MCF7（乳腺癌）、HOS（骨肉瘤）和 THP-1（单核细胞白血病）的体外细胞毒性，确定复合物 4-6 是最有希望的代表，其抗增殖活性是进一步针对 A549（肺腺癌）、G-361（黑色素瘤）、HeLa（宫颈癌）、A2780（卵巢癌）、A2780R（对顺铂耐药的卵巢癌）进行了测试，22Rv1（前列腺癌）细胞系。与商业使用的抗癌药物顺铂相比，复合物 4-6 对所用癌细胞（G-361 除外）显示出显着更高的体外抗癌作用，IC50 ≈ 1-30 µM。通过评估复合物调节促炎细胞因子（
• Therapeutic nucleosides
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0286425A2

  公开（公告）日：1988-10-12

  This invention relates to certain 6-substituted 2ʹ,3ʹ-dideoxypurine nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment and prophylaxis of HIV infections. Also provided are pharmaceutical formulations and processes for the production of the compounds according to the invention.

  本发明涉及某些6-取代的2ʹ,3ʹ-二脱氧嘌呤核苷及其药学上可接受的衍生物，以及它们在治疗和预防HIV感染中的用途。还提供了根据本发明的化合物的药物制剂和生产工艺。
• Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same
  申请人：Takara Bio USA, Inc.

  公开号：US10584363B2

  公开（公告）日：2020-03-10

  Methods of producing single-stranded deoxyribonucleic acids (ssDNAs) are provided. Aspects of the methods include generating a double stranded deoxyribonucleic acid (dsDNA) and then selectively degrading one strand of the dsDNA to produce a ssDNA. ssDNAs produced using methods of the invention find use in a variety of applications, including genomic modification applications. Also provided are compositions, e.g., kits, that find use in practicing various embodiments of the invention.

  本文提供了生产单链脱氧核糖核酸（ssDNA）的方法。 这些方法的各个方面包括产生双链脱氧核糖核酸（dsDNA），然后选择性地降解dsDNA的一条链以产生ssDNA。使用本发明方法产生的ssDNA可用于各种应用，包括基因组修饰应用。 此外，还提供了可用于实施本发明各种实施方案的组合物，如试剂盒。
• Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
  申请人：Friedrich-Alexander-Universität Erlangen-Nürnberg

  公开号：US10828281B2

  公开（公告）日：2020-11-10

  The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

  本发明涉及其化合物、同系物、立体异构体和化学修饰化合物，及其在预防和/或治疗肿瘤转移和/或软骨缺损中的用途，以及包含此类化合物的药物组合物。
• Methods for detecting agglutination and compositions for use in practicing the same
  申请人：The Regents of the University of California

  公开号：US11149296B2

  公开（公告）日：2021-10-19

  Methods are provided for detecting antigen binding agents in samples. Aspects of the methods include detection of the aggregation of antigen binding agents with polynucleotide-bound antigens by sensitive proximity-based association of the antigen-bound polynucleotides. Aspects of the methods also include methods for the detection of such proximity-based association through nucleic acid amplification. In addition, compositions, e.g., reagents, kits, and devices, useful in practicing various embodiments of the methods are provided.

  提供了检测样品中抗原结合剂的方法。这些方法的各个方面包括通过与抗原结合的多核苷酸的灵敏近距离结合来检测抗原结合剂与多核苷酸结合抗原的聚集。这些方法的各个方面还包括通过核酸扩增来检测这种基于近距离结合的方法。此外，还提供了有助于实施本方法各实施例的组合物，如试剂、试剂盒和装置。